Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

EE Freeman, RG White, Roel Bakker, KK Orroth, HA Weiss, A Buve, RJ Hayes, JR Glynn

Research output: Contribution to journalArticleAcademicpeer-review

37 Citations (Scopus)

Abstract

Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. intensified efforts are needed to develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)940-946
Number of pages7
JournalVaccine
Volume27
Issue number6
DOIs
Publication statusPublished - 2009

Cite this